LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,226
تعداد مقالات11,166
تعداد مشاهده مقاله77,063,835
تعداد دریافت فایل اصل مقاله101,266,292
Khorramizadeh, Maryam, Arab-Bafranie, Zahra, Kassani, Aziz, Banazadeh, Nilofar, Ghasemi, Manouchehr. (1404). Oridonin Enhances Radiotherapy Efficacy by Inducing Late-Stage Cell Death and G2/M Arrest in U87MG Glioma Cells. سامانه مدیریت نشریات علمی, 16(4), 334-345. doi: 10.30476/mejc.2025.103211.2130
Maryam Khorramizadeh; Zahra Arab-Bafranie; Aziz Kassani; Nilofar Banazadeh; Manouchehr Ghasemi. "Oridonin Enhances Radiotherapy Efficacy by Inducing Late-Stage Cell Death and G2/M Arrest in U87MG Glioma Cells". سامانه مدیریت نشریات علمی, 16, 4, 1404, 334-345. doi: 10.30476/mejc.2025.103211.2130
Khorramizadeh, Maryam, Arab-Bafranie, Zahra, Kassani, Aziz, Banazadeh, Nilofar, Ghasemi, Manouchehr. (1404). 'Oridonin Enhances Radiotherapy Efficacy by Inducing Late-Stage Cell Death and G2/M Arrest in U87MG Glioma Cells', سامانه مدیریت نشریات علمی, 16(4), pp. 334-345. doi: 10.30476/mejc.2025.103211.2130
Khorramizadeh, Maryam, Arab-Bafranie, Zahra, Kassani, Aziz, Banazadeh, Nilofar, Ghasemi, Manouchehr. Oridonin Enhances Radiotherapy Efficacy by Inducing Late-Stage Cell Death and G2/M Arrest in U87MG Glioma Cells. سامانه مدیریت نشریات علمی, 1404; 16(4): 334-345. doi: 10.30476/mejc.2025.103211.2130

Oridonin Enhances Radiotherapy Efficacy by Inducing Late-Stage Cell Death and G2/M Arrest in U87MG Glioma Cells

Middle East Journal of Cancer
مقاله 3، دوره 16، شماره 4، دی 2025، صفحه 334-345    اصل مقاله (3.86 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/mejc.2025.103211.2130
نویسندگان
Maryam Khorramizadeh* 1؛ Zahra Arab-Bafranie2؛ Aziz Kassani3؛ Nilofar Banazadeh4؛ Manouchehr Ghasemi5
1Department of Medical Physics, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
2Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran
3Department of Community Medicine, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
4School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
5Imam Hassan Mojtaba Radiotherapy-Oncology Center, Dezful, Iran
چکیده
Background: Glioblastoma multiforme is a deadly brain tumor with limited treatment options. The aim of this study was to investigate whether oridonin (OR) could enhance the radiosensitivity of U87MG glioma cancer cells, and compare this effect with that of temozolomide (TMZ).
Method: In this experimental study, we investigated the effects of OR on U87MG glioma cells, alone and in combination with radiotherapy and TMZ cell viability assay, cell cycle analysis, and apoptosis assays were performed to assess the impact of these treatments. The differences between groups were assessed using nonparametric tests including Wilcoxon and chi-square using GraphPad Prism software.
Results: OR showed dose-dependent cytotoxicity in U87MG glioma cells. Radiation further enhanced the anti-proliferative effect of OR. TMZ, a standard treatment, also showed significant cytotoxicity, especially with radiation. Both treatments induced G2/M cell cycle arrest, particularly when combined with radiation. Notably, OR and radiation caused a more pronounced G2-phase arrest (55.6%) than TMZ (39.9%) (P < 0.001). While neither treatment significantly affected early apoptosis, both increased late-stage cell death. Importantly, OR and radiation significantly increased late-stage cell death (60.07 ± 1.4%) compared with TMZ and radiation alone (48.04 ± 2.9%) (P = 0.02).
Conclusion: These findings suggest the potential of OR as a radiosensitizer for Glioblastoma multiforme treatment. Further research is needed to understand the mechanisms and validate these results in living organisms. This paves the way for exploring OR as a radiosensitizer for Glioblastoma multiforme treatment in the future.

تازه های تحقیق

Maryam Khorramizadeh (Google Scholar)

کلیدواژه‌ها
Glioma؛ X-rays؛ Temozolomide؛ Cells؛ Apoptosis
مراجع
  1. Mahzouni P, Seddighin R, Mousaei Ghasroldasht M. Evaluation of TRAF3IP2 gene expression in brain tumor tissue of patients with glioblastoma multiforme in comparison to non-tumoral brain tissue. Middle East J Cancer. 2023;14:543-9. doi: 10.30476/mejc.2023.96063.1800.
  2. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020;70(4):299-312. doi: 10.3322/caac.21613. PMID: 32478924.
  3. Mathen P, Rowe L, Mackey M, Smart D, Tofilon P, Camphausen K. Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma. Neurooncol Pract. 2020;7:268-76. doi: 10.1093/nop/npz057. PMID: 32537176; PMCID: PMCPMC7274183.
  4. Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, et al. A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2015;92:986-92. doi: 10.1016/j.ijrobp.2015.04.038. PMID: 26194676; PMCID: PMCPMC4510472.
  5. Yun HS, Lee J, Kil WJ, Kramp TR, Tofilon PJ, Camphausen K. The radiosensitizing effect of AZD0530 in glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther. 2021;20:1672-9. doi: 10.1158/1535-7163.mct-20-0883. PMID: 34158343; PMCID: PMCPMC8419151.
  6. Borhani S, Mozdarani H, Babalui S, Bakhshandeh M, Nosrati H. In vitro radiosensitizing effects of temozolomide on U87MG cell lines of human glioblastoma multiforme. Iran J Med Sci. 2017;42:258-65. PMID: 28533574; PMCID: PMCPMC5429494.
  7. Hwang K, Lee JH, Kim SH, Go KO, Ji SY, Han JH, et al. The combination PARP inhibitor Olaparib with temozolomide in an experimental glioblastoma model. In Vivo. 2021;35:2015-23. doi: 10.21873/invivo.12470. PMID: 34182476; PMCID: PMC8286506.
  8. van Erp AEM, van Houdt L, Hillebrandt-Roeffen MHS, van Bree NFHN, Flucke UE, Mentzel T, et al. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. J Cancer Res Clin Oncol. 2020;146(7):1659-70. doi: 10.1007/s00432-020-03211-z. PMID: 32279088; PMCID: PMC7256072.
  9. Xie Y, Han Y, Zhang X, Ma H, Li L, Yu R, et al. Application of new radiosensitizer based on nano-biotechnology in the treatment of glioma. Front Oncol. 2021;11:633827. doi: 10.3389/fonc.2021.633827. PMID: 33869019; PMCID: PMC8044949.
  10. Liu S, Zhou L, Zhao Y, Yuan Y. β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway. Oncol Rep. 2015;34(2):943-51. doi: 10.3892/or.2015.4050.
  11. Mahdizade Valojerdi F, Goliaei B, Rezakhani N, Nikoofar A, Keshmiri Neghab H, Soheilifar MH, et al. In vitro radiosensitization of T47D and MDA-MB-231 breast cancer cells with the neoflavonoid dalbergin. Middle East J Cancer. 2023;14(2):205-18. doi: 10.30476/mejc.2022.91913.1637.
  12. Li S, Shi D, Zhang L, Yang F, Cheng G. Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl-2. Exp Ther Med. 2018;16(6):4859-64. doi: 10.3892/etm.2018.6803. PMID: 30546402; PMCID: PMC6256844.
  13. Xia S, Zhang X, Li C, Guan H. Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm J. 2017;25(4):638-43. doi: 10.1016/j.jsps.2017.04.037. PMID: 28579904; PMCID: PMC5447451.
  14. Zhang P, Zhao SR, Liu F, Sun XJ, Liu H. Oridonin induces apoptosis in human nasopharyngeal carcinoma cells involving ROS generation. Folia Biol (Praha). 2017;63(4):155-63. PMID: 29256858.
  15. Zhang XH, Liu YX, Jia M, Han JS, Zhao M, Ji SP, et al. Oridonin inhibits tumor growth in glioma by inducing cell cycle arrest and apoptosis. Cell Mol Biol (Noisy-le-grand). 2014;60(6):29-36. PMID: 25553351.
  16. Park H, Jeong YJ, Han NK, Kim JS, Lee HJ. Oridonin enhances radiation-induced cell death by promoting DNA damage in non-small cell lung cancer cells. Int J Mol Sci. 2018;19(8):2378. doi: 10.3390/ijms19082378. PMID: 30104472; PMCID: PMC6121891.
  17. Yao Z, Xie F, Li M, Liang Z, Xu W, Yang J, et al. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells. Cell Death Dis. 2017;8(2):e2633. doi: 10.1038/cddis.2017.35. PMID: 28230866; PMCID: PMC5386482.
  18. Sun B, Wang G, Liu H, Liu P, Twal WO, Cheung H, et al. Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget. 2018;9(35):23878-89. doi: 10.18632/oncotarget.24378. PMID: 29844859; PMCID: PMC5963618.
  19. Harder BG, Blomquist MR, Wang J, Kim AJ, Woodworth GF, Winkles JA, et al. Developments in blood-brain barrier penetrance and drug repurposing for improved treatment of glioblastoma. Front Oncol. 2018;8:462. doi: 10.3389/fonc.2018.00462. PMID: 30406029; PMCID: PMC6206841.
  20. Li N, Zhang P, Kiang KMY, Cheng YS, Leung GKK. Caffeine sensitizes U87-MG human glioblastoma cells to temozolomide through mitotic catastrophe by impeding G2 arrest. Biomed Res Int. 2018;2018:5364973. doi: 10.1155/2018/5364973. PMID: 30050935; PMCID: PMC6046144.
  21. Lu J, Chen X, Qu S, Yao B, Xu Y, Wu J, et al. Oridonin induces G2/M cell cycle arrest and apoptosis via the PI3K/Akt signaling pathway in hormone-independent prostate cancer cells. Oncol Lett. 2017;13(4):2838-46. doi: 10.3892/ol.2017.5751PMID: 28454475; PMCID: PMC5403405.
  22. Bao R, Shu Y, Wu X, Weng H, Ding Q, Cao Y, et al. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer. 2014;14(1):217. doi: 10.1186/1471-2407-14-217.
  23. Chen S, Gao J, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol. 2005;26(3):579-88. PMID: 15703811.
  24. Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, et al. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin. 2007;28(7):1057-66. doi: 10.1111/j.1745-7254.2007.00588.x. PMID: 17588343.
آمار
تعداد مشاهده مقاله: 430
تعداد دریافت فایل اصل مقاله: 153


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب